Chemoprevention strategies for high risk women

Current Women's Health Reviews

Volumn 8, Issue 1, 2012, Pages 86-93

  Toss, Angela ^a   Sebastiani, Federica ^a   Razzaboni, Elisabetta ^a   de Matteis, Elisabetta ^a   Marchi, Isabella ^a   Proietto, Manuela ^a   Cortesi, Laura ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Aromatase inhibitor; Breast cancer; Chemoprevention; Raloxifene; SERM

Indexed keywords

ACOLBIFENE; ALPHA TOCOPHEROL; ANASTROZOLE; ARZOXIFENE; ASCORBIC ACID; CYCLOOXYGENASE 2 INHIBITOR; EFLORNITHINE; EXEMESTANE; FENRETINIDE; HISTONE DEACETYLASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOFLAVONE DERIVATIVE; LETROZOLE; METALLOPROTEINASE INHIBITOR; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RALOXIFENE; RETINOID; SELENIUM; TAMOXIFEN; TERPENE; VITAMIN D;

ARTICLE; BREAST CANCER; CANCER PREVENTION; CHEMOPROPHYLAXIS; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84858304439     PISSN: 15734048     EISSN: 18756581     Source Type: Journal    
DOI: 10.2174/157340412799079174     Document Type: Article

References (66)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2): 74-108.
2. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000; 355: 1822-1823.
3. EBCTCG-Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 1-15, 71-85.
4. EBCTCG-Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351: 1451-1467.
5. Fisher B, Costantino J, Redmond C, et al. A randomised clinical trial evaluating tamoxifen in the treatment of patients with node negative breast cancer who have oestrogen receptor positive tumors. N Engl J Med 1989; 320: 479-484.
6. Fornander T, Cedermark B, Mattsson A. et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; 1(8630): 117-120.
7. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352: 98-101.
8. Powles TJ, Tillyer CR, Jones AL, et al. Prevention of breast cancer with tamoxifen -an update on the Royal Marsden Hospital pilot programme. Eur J Cancer 1990; 26: 680-684.
9. Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007; 99(4): 283-290.
10. Veronesi U, Maisonneuve P, Sacchini V, et al. Tamoxifen for breast cancer among hysterectomised women. Lancet 2002; 359: 1122-1124.
11. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. JNCI 1998; 90: 1371-1387.
12. Cuzick J, Howell A. A brief review of the breast cancer prevention trials. Eur. J. Cancer 2000; 36: S51-S53.
13. Cuzick J, Powles T, Veronesi U, et al. Overview of the Main Outcomes in Breast Cancer Prevention Trials. Lancet 2003; 361: 296-300.
14. Fallowfield L, Fleissig A, Edwards R, et al. Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol 2001; 19: 1885-1892.
15. Cuzick J, Forbes JF, Sestak I, et al. Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer: 96-Month Follow-up of the Randomized IBIS-I Trial. J Natl Cancer Inst 2007; 99(4): 272-282.
16. Cuzick J, Forbes J, Edwards R, et al. First Results from the IBIS-I Breast Cancer Prevention Trial. Lancet 2002; 360: 817-824.
17. Decensi A, Bonanni B, Guerrieri-Gonzaga A, et al. Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 1998; 90: 1461-1467.
18. Decensi A, Gandini S, Guerrieri-Gonzaga A, et al. Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction. J Clin Oncol 1999; 17: 2633-2638.
19. Decensi A, Robertson C, Viale G, et al. A randomized trial of lowdose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 2003; 95: 779-790.
20. Guerrieri-Gonzaga A, Botteri E, Lazzeroni M, et al. Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study. Ann Oncol 2010; 21(5): 949-954.
21. Bonanni B, Macis D, Maisonneuve P, et al. Polymorphism in the CYP2D6 tamoxifen metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol 2006; 24: 3708-3709.
22. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007; 101(1): 113-121.
23. Serrano D, Lazzeroni M, Zambon CF, et al. Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial. Pharmacogenomics J 2011; 11(2): 100-107.
24. Cazzaniga M, Decensi A, Bonanni B, Luini A, Gentilini O. Biomarkers for risk assessment and prevention of breast cancer. Curr Cancer Drug Targets 2009; 9(4): 482-499.
25. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentration of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351: 1393-1396.
26. Johansson H, Baglietto L, Guerrieri-Gonzaga A, et al. Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer. Breast Cancer Res Treat 2004; 88: 63-73.
27. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 1999; 281: 2189-2197.
28. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4- year results from the MORE trial. Breast Cancer Res Treat 2001; 65(2): 125-134.
29. Martino S, Cauley JA, Barret-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004; 96(23): 1751-1761.
30. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355(2): 125-137.
31. Grady D, Cauley JA, Geiger MJ, et al. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. J Natl Cancer Inst 2008; 100: 854-861.
32. Wickerham DL, Costantino JP, Vogel VG, et al. The use of tamoxifen and raloxifene for the prevention of breast cancer. Recent Result Cancer Res 2009; 181: 113-119.
33. Vogel VG. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Rev Anticancer Ther 2009; 9(1): 51-60.
34. Cuzick J. Chemoprevention of breast cancer. Breast Cancer 2008; 15: 10-16.
35. Jakesz R, Hausmaninger H, Samonigg H, et al. Comparison of adjuvant therapy with tamoxifen and goserelin vs CMF in premenopausal stage I and II hormone-responsive breast cancer patients: Four-year results of Austrian Breast Cancer Study Group (ABSCG) Trial 5. Eur J Cancer 1999; 35(Suppl 4): S83-S83.
36. Rutqvist LE. Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: a randomised trial by the Cancer Research Campaign (CRC) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group, the South-East Sweden Breast Cancer Group and the Gruppo Interdisciplinare Valutazione Interventi in Oncologia (GIVIO). Proc. ASCO 1999; 18: 67a.
37. Buzdar A, Bonneterre J, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer (ABC) in postmenopausal (PM) women. Findings highlight the importance of receptor status assessment prior to treatment initiation. Ann Oncol 2000; 11(Suppl 4): 25.
38. Gibson LJ, Dawson CK, Lawrence DH, Bliss JM. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 2007; (1): CD003370.
39. Riemsma R, Forbes CA, Kessels A, et al. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. Breast Cancer Res Treat 2010; 123: 9-24.
40. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as firstline therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18(22): 3758-3767.
41. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18(22): 3748-3757.
42. Mouridsen HT. Letrozole in advanced breast cancer: the PO25 trial. Breast Cancer Res Treat 2007; 105(Suppl-1): 19-29.
43. Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008; 26(30): 4883-4890.
44. Wolfgang J, Philip H. Adjuvant aromatase inhibitor therapy: Outcomes and safety. Cancer Treat Rev 2010; 36(3): 249-261.
45. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100- month analysis of the ATAC trial. Lancet Oncol 2008; 9(1): 45-53.
46. Joerger M, Thürlimann B. Update of the BIG 1-98 Trial: where do we stand? Breast 2009; 18(Suppl 3): S78-S82.
47. Jones SE, Seynaeve C, Hasenburg A, et al. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast. Cancer Res 2009; 69: 67s. [abstract 15].
48. Coombes RC, Kilburn LS, Snowdon CF, et al. Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369: 559-570.
49. Kaufmann M, Jonat W, Hilfrich J, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol 2007; 25: 2664-2670.
50. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptorpositive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97: 1262-1271.
51. Dunn BK, Ryan A. Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of selective estrogen receptor modulators. Ann N Y Acad Sci 2009; 1155: 141-161.
52. Fabian CJ. Breast cancer chemoprevention: beyond tamoxifen. Breast Cancer Res 2001; 3: 99-103.
53. Costa A, Sacchini V, Decensi A. Retinoids and tamoxifen in breast cancer chemoprevention. Int J Clin Lab Res 1993; 23: 53-55.
54. Decensi A, Robertson C, Guerrieri-Gonzaga A, et al. Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J Clin Oncol 2009; 27: 3749-3756
55. Baron JA, Sandler RS, Bresalier RS, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 2008; 372(9651):1756-1764.
56. Julian-Reyner CM, Bouchard LJ, Evans DG, et al. Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. Cancer 2001; 92(4): 959-968.
57. Lovegrove E, Rumsey N, Harcourt D, et al. Factors implicated in the decision whether or not to join the tamoxifen trial in women at high familial risk of breast cancer. Psycho-Oncology 2000; 9: 193-202.
58. Port ER, Montgomery LL, Heerdt AS, et al. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 2001; 8(7): 580-585.
59. Rondanina G, Puntoni M, Severi G, et al. Psychological and clinical factor implicated in decisin making about a trial of low-dose tamoxifen in hormone replacement therapy users. J Clin Oncol 2008; 26(9): 1537-1543.
60. Cyrus-Davis MS, Strom SS. Chemoprevention of breast cancer with selective estrogen receptor modulators: views from broadly diverse focus group of women with elevated risk for breast cancer. Psychooncology 2001; 10(6): 521-533.
61. Bober SL, Hoke AL, Duda RB, Regan EM, Tung NM. Decision- Making About Tamoxifen in Women at High Risk for Breast Cancer: Clinical and Psychological Factors. J Clin Oncol 2004; 22(24): 4951-4957.
62. Heisey R, Pimlott N, Clemons M, Cummings S, Drummond N. Women's views on chemoprevention of breast cancer. Qualitative study. Can Fam Physician 2006; 52: 624-625.
63. Pritchard KI. Is tamoxifen effective in prevention of breast cancer? Lancet 1998; 352: 80-81.
64. Maurice A, Howell A, Evans DG, O'Neil AC, Scobie S. Predicting Compliance in a Breast Cancer Prevention Trial. Breast J 2006; 12(5): 446-450.
65. Evans D, Lalloo F, Shenton A, Bogges C, Howell A. Uptake of screening and prevention in women at very high risk of breast cancer. Lancet 2001; 358: 889-890.
66. Haugan Moi LL, Hauglid Flågeng M, Gandini S, et al. Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue. Clin Cancer Res 2010; 16(7): 2176-2186.